Sales Advance at Noven

Barrett says the guidance regarding Daytrana includes replacement products for a recall on the patch. Some of the patches had problems with their adhesive and were difficult to peel.

"That issue impacted about 2% of prescriptions," said Joseph Jones, vice president of corporate affairs, on the conference call. "The enhancements took place in the first quarter, and those products are in the channel as we speak. There will be no further implications in the next quarter from replacing that product."

Looking forward, Robert Strauss, chief executive and chairman, said the company is working on five or more experimental products and is seeking an acquisition to add a commercialization arm that would increase its sales force by 50 to 100 representatives.

Shares of Noven were recently up 29 cents, or 1.2%, to $24.20.